Trial reportBiomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals2012
Galectin 3 complements BNP in risk stratification in acute heart failure.
Trial report in Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it, 53 citations in OpenAlex.
- Transfusion-associated circulatory overload-a systematic review of diagnostic biomarkers.Transfusion · 2019Pooled it
- Challenges of Biomarker Application in Patients with Cardiorenal Syndrome.Biomedicines · 2026Review
- Use of Natriuretic Peptides in Critically Ill Patients: A Narrative Review.Journal of clinical medicine · 2026Review
- Omaveloxolone, But Not Dimethyl Fumarate, Improves Cardiac Function in Friedreich's Ataxia Mice With Severe Cardiomyopathy.Journal of the American Heart Association · 2025Article
- Circulating galectin-3 level association with cardiovascular risk factors during peritoneal dialysis.Clinical and experimental nephrology · 2024Article
- The Role of Galectin-3 in Heart Failure-The Diagnostic, Prognostic and Therapeutic Potential-Where Do We Stand?International journal of molecular sciences · 2023Review
- The Diagnostic and Therapeutic Potential of Galectin-3 in Cardiovascular Diseases.Biomolecules · 2021Review
- The diagnostic and prognostic value of galectin-3 in patients at risk for heart failure with preserved ejection fraction: results from the DIAST-CHF study.ESC heart failure · 2021Article
- N-terminal pro BNP and galectin-3 are prognostic biomarkers of acute heart failure in sub-Saharan Africa: lessons from the BAHEF trial.ESC heart failure · 2021Article
- Galectin-3 as a marker for clinical prognosis and cardiac remodeling in acute heart failure.Herz · 2018Article
- Galectin-3: a novel biomarker for the prognosis of heart failure.Clujul medical (1957) · 2017Review
- Assessment of Galectin-3 Polymorphism in Subjects with Chronic Chagas Disease.Arquivos brasileiros de cardiologia · 2015Observational
- Long-term sequelae from acute kidney injury: potential mechanisms for the observed poor renal outcomes.Critical care (London, England) · 2015Review
- Review of the prognostic value of galectin-3 in heart failure focusing on clinical utility of repeated testing.Molecular diagnosis & therapy · 2014Review
- Determinants of survival following hospitalization for acute heart failure.Current heart failure reports · 2014Review
- Clinical use of novel biomarkers in heart failure: towards personalized medicine.Heart failure reviews · 2014Review
- The emerging role of Galectin-3 and ST2 in heart failure: practical considerations and pitfalls using novel biomarkers.Current heart failure reports · 2013Review
- Stem cell therapy for chronic heart failure: an updated appraisal.Expert opinion on biological therapy · 2013Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 4 institutions in 1 country.
Funding
Abstract
backgroundGalectin 3 (G3) is a mediator of fibrosis and remodeling in heart failure.
methodsPatients diagnosed with and treated for Acute Heart Failure Syndromes were prospectively enrolled in the Decision Making in Acute Decompensated Heart Failure multicenter trial.
resultsPatients with a higher G3 had a history of renal disease, a lower heart rate and acute kidney injury. They also tended to have a history of HF and 30-day adverse events compared with B-type natriuretic peptide.
conclusionIn Acute Heart Failure Syndromes, G3 levels do not provide prognostic value, but when used complementary to B-type natriuretic peptide, G3 is associated with renal dysfunction and may predict 30-day events.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.